Skip to main content.

Advances in the Treatment of Hematologic Malignancies and Cellular Therapeutics

Advances in the Treatment of Hematologic Malignancies and Cellular Therapeutics Symposium is an annual conference sponsored by The University of Kansas Cancer Center Blood and Marrow Transplant Program, National Marrow Donor Program "Be the Match" and the University of Kansas Medical Center's Area Health Education Center.

register today for the 2022 Symposium

About the Symposium

The conference offers a review of the latest advances in the field of autologous and allogeneic (related and unrelated donor) blood and marrow transplantation, including current state-of-the-art treatment strategies, clinical trials research, and outcomes of both autologous and allogeneic transplants to aid in your clinical decision making.

For more information, download the 2022 Symposium Informational Brochure (PDF)

2022 Symposium Agenda

8:45 a.m.
Welcome and Introduction
Joseph McGuirk, DO

9:00 a.m.
Advances in Stem Cell Transplantation and CAR-T/Cell Therapies: Key Contributions from 2022 ASTCT/CIBMTR Transplantation and Cellular Therapy (TCT) Meeting
Joseph McGuirk, DO

9:30 a.m.
The Prevention and Treatment of Post-Transplant Relapse
Robert Soiffer, MD

10:15 a.m.

10:30 a.m.
Preventing Post-Transplant Relapse with Targeted Therapies
Mark Levis, MD

11:15 a.m.
Novel Constructs and the New Era or CAR-T Cell Therapy
Yvonne Chen, MD

12:00 p.m.
Afternoon Break/Lunch

12:30 p.m.
Mitigating Toxicities Associated with CAR-T Cell Therapies
Saad Kenderian, MD

1:30 p.m.

Provider Track

1:45 p.m.
1P: Updates in the Treatment of High Risk Lymphoma: SCT vs CAR-T
Mehdi Hamadani, MD

2:30 p.m.
2P: Survivorship and Late Effects After Stem Cell Transplantation & CAR-T
Nausheen Ahmed, MD

Nursing Track*

1:45 p.m.
1N: The Management of CAR-T and Cell Therapy Patients
Stephanie Nigro, RN, MSN, BMTCN

2:30 p.m.
2N: Nursing Implications for BMT/Cell Therapy Survivorship Patients
Cheri Morey, APRN, and Sara Fitzmaurice, APRN

Nurses may attend any of the Provider or Nursing Track presentations.

3:15 p.m.
Q & A Session
Reception to follow

2022 Speakers

Nausheen Ahmed, M.D.

Dr. Ahmed recently joined us as an assistant professor in the division of hematologic malignancies and cellular therapy. She serves as the Assistant Director for Cellular Therapeutics and Medical Director of the Transplant Survivorship Program for the Division of Hematological Malignancies and Cellular Therapy at the University of Kansas Medical Center. Dr. Ahmed finished her training in hematology/oncology from Tufts University/Baystate and then pursued advanced training in stem cell transplant and cellular therapy at Case Western Reserve University. Her clinical interests include cellular therapy and transplant for lymphoma, myeloma and myeloid malignancies, and survivorship. She is interested in studying the mechanism of resistance and relapse in lymphoma and myeloma post CAR-T and transplant and the role of maintenance therapies post-transplant. Her interests also include improving access to care and studying the long-term effects of transplants and quality of life.

Follow her on twitter @NausheenAhmedMD

Yvonne Chen, M.D.

Dr. Yvonne Chen is an Associate Professor of Microbiology, Immunology, and Molecular Genetics at the University of California, Los Angeles. She is also a faculty, by courtesy, in the Department of Chemical and Biomolecular Engineering. Yvonne is the co-director of the Tumor Immunology program in the Jonsson Comprehensive Cancer Center at UCLA, and a member researcher of the Parker Institute for Cancer Immunotherapy. The Chen Laboratory applies synthetic biology and biomolecular engineering techniques to the development of novel mammalian-cell systems for clinical use and led the first investigator-initiated clinical trial on CAR-T cell therapy at UCLA. The Chen Lab’s work on engineering next-generation T-cell therapies for cancer has been recognized by the NIH Director’s Early Independence Award, the NSF CAREER Award, the Hellman Fellowship, the ACGT Young Investigator Award in Cell and Gene Therapy for Cancer, the Mark Foundation Emerging Leader Award, and the Cancer Research Institute Lloyd J. Old STAR Award. Prior to joining UCLA in 2013, Yvonne was a Junior Fellow in the Harvard Society of Fellows. She received postdoctoral training at the Seattle Children’s Research Institute, and in the Department of Systems Biology at Harvard Medical School. Yvonne received her B.S. in Chemical Engineering from Stanford University and her Ph.D. in Chemical Engineering from the California Institute of Technology.

Sarah Fitzmaurice, APRN

Bio coming soon.

Mehdi Hamadani, M.D.

Bio coming soon.

Saad Kenderian, M.D.

Dr. Kenderian is a consultant in hematology at the Mayo Clinic Rochester, with joint appointments in the Department of Immunology and Department of Molecular Medicine. He holds the academic rank of Assistant Professor of Medicine, Oncology, and Immunology in Mayo Clinic College of Medicine. As a physician-scientist, he directs a federally funded translational laboratory program focused on T cell biology, cellular engineering, and chimeric antigen receptor T (CART) cell therapy. In this context, he collaborates with multiple pharmaceutical and biotech companies. Since 2019, three clinical trials have been translated from his laboratory, two of them are multi-center trials. He has authored more than 90 manuscripts and book chapters. He is an inventor on multiple patent applications and is the Principal Investigator on 5 active clinical trials.

Mark Levis, M.D.

Bio coming soon.

Joseph McGuirk, D.O.

Dr. Joseph McGuirk completed an internal medicine residency at Yale New Haven Hospital, and oncology fellowship at Memorial Sloan Kettering Cancer Center. He returned to Yale to serve as Associate Director of the BMT Program and then joined the University of Kansas Medical Center/The University of Kansas Cancer Center in 2007 and in 2015 he created the Division of Hematologic Malignancies and Cellular Therapeutics (HMCT). Dr. McGuirk currently serves as the Schutte-Speas Professor in Hematology-Oncology and the Division Director of Hematologic Malignancies and Cellular Therapeutics at the University of Kansas Health System. He actively serves on numerous editorial review boards, has authored/co-authored over 280 peer-reviewed abstracts and publications, and serves on several committee assignments including the American Society for Blood and Marrow Transplantation (ASBMT) Board of Directors. Dr. McGuirk has obtained considerable insight and expertise as a PI on over 80 clinical trials, including numerous pharmaceutical-sponsored, NCI and NIH-funded investigational clinical trials. He has presented at more than a dozen universities and associations, including Dana-Farber Cancer Center and Beth Israel Hospital in Boston, the Chinese Academy of Medical Sciences and Peking Union Medical College in Beijing, the American Society of Hematology Annual Meeting and the Kansas Association of Osteopathic Medicine. As Division Director he is responsible for a rapidly growing division and creating a safe clinical program that is compassionate, efficient, patient and physician-friendly clinical program at the NCI-Designated University of Kansas Cancer Center. The Division currently has 10 hematologists, 10 bone marrow transplant physicians, and 2 researchers. Our FACT-accredited BMT program is the only adult program in the region, which was established in 1977 and has performed over 3,500 transplants since its inception. The current program has grown to approximately 325 transplants per year. Our program performs all types of transplants (e.g. Autologous, Syngeneic, Allogeneic related and unrelated donor transplants, including cord blood and haplo-identical donors). It is also National Marrow Donor Program (NMDP) accredited; and the only NMDP donor collection center in KS (1 of 96 in nation). Our BMT program also has one of the largest Photopheresis programs in the nation and the only BMT survivorship and GVHD clinics in the region. The HMCT program utilizes algorithms and clinical care pathways based upon published, best practices to avoid care variations and ensure optimal patient outcomes.

Cherie Morie, APRN

Cherie Morey is a Nurse Practitioner at University of Kansas Cancer Center’s Blood and Marrow Transplant program. She specializes in Cancer Survivorship for patients after Marrow Transplantation and Cellular Therapy. She completed her Bachelor of Science in Nursing and went on the earn her Master Of Science as a Family Nurse Practitioner at the University of Kansas in Kansas City. She holds a national certification as a Family Nurse Practitioner with the American Association of Nurse Practitioners and holds certification as tobacco cessation specialist.

Stephanie Nigro, RN, M.S.N., BMTCN

Bio coming soon.

Robert Soiffer, M.D.

Bio coming soon.

2022 Advances in the Treatment of Hematologic Malignancies and Cellular Therapeutics Support Opportunities

Want to help support the 2022 Symposium? Now is your chance to become a sponsor, exhibitor, or donor. Click the button below for more information.

Support the 2022 Symposium
Community Engagement

University of Kansas Medical Center
KU Area Health Education Center
1501 S. Joplin
4th Floor, Shirk Hall
Pittsburg, KS 66762
Phone: 620-235-4040